ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company’s pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

Read this article:
First patient enrolled in Contravir ‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Scroll to Top